Mallinckrodt slumps as Achtar drug sales disappoint

(Reuters) - Shares of Mallinckrodt Plc were down about 9 percent in premarket trading on Tuesday after the drugmaker reported lower-than-expected quarterly revenue, hurt mainly by weak sales of its Acthar drug.